Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | HPGD | P15428 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL987234 | 0.88 | ALDH1A1 (0.42) | ALDH1A1HPGDKDM4EHTTRECQL | |
| SCHEMBL7883597 | 0.87 | ALDH1A1 (0.41) | ALDH1A1HPGDKDM4EHTTRECQL | |
| Water SCHEMBL21776630 | 0.87 | ALDH1A1 (0.41) | ALDH1A1HPGDKDM4EHTTRECQL | |
| SCHEMBL7878657 | 0.86 | ALDH1A1 (0.40) | ALDH1A1HPGDKDM4EHTTRECQL | |
| SCHEMBL7298547 | 0.86 | ALDH1A1 (0.40) | ALDH1A1HPGDKDM4EHTTRECQL | |
| SCHEMBL8861128 | 0.85 | ALDH1A1 (0.40) | ALDH1A1HPGDKDM4EHTTRECQL | |
| SCHEMBL8244423 | 0.82 | ALDH1A1 (0.48) | ALDH1A1HPGDKDM4EHTTRECQL | |
| SCHEMBL7885555 | 0.81 | ALDH1A1 (0.41) | ALDH1A1HPGDKDM4EHTTRECQL | |
| SCHEMBL9256737 | 0.80 | CACNA1G (0.43) | ALDH1A1HPGDKDM4EHTTRECQL | |
| SCHEMBL7878648 | 0.79 | KDM4E (0.43) | ALDH1A1HPGDKDM4EHTTRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1988091-B1 | TRICYCLIC COMPOUNDS | KYOWA HAKKO KIRIN CO LTD (JP) | 2015-06-10 | — | — | EP | disclosed |
| US-8242151-B2 | Tricyclic compounds | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2012-08-14 | — | — | US | disclosed |
| US-20090176760-A1 | TRICYCLIC COMPOUNDS | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-07-09 | — | — | US | disclosed |
| EP-1988091-A1 | TRICYCLIC COMPOUNDS | Kyowa Hakko Kogyo Co., Ltd (JP) | 2008-11-05 | — | — | EP | disclosed |
| CN-1121859-C | Process for preparing pharmaceutical composition for treatment or prevention hypertension | SNAKYO CO LTD (JP) | 2003-09-24 | — | — | CN | disclosed |
| CN-1101384-C | Process for preparing 1-biphenylmethylimidazole derivatives | SANKYO CO (JP) | 2003-02-12 | — | — | CN | disclosed |
| EP-0503785-B1 | 1-Biphenylimidazole derivatives, their preparation and their therapeutic use | SANKYO CO (JP) | 2001-04-25 | — | — | EP | disclosed |
| CN-1045770-C | Process for preparing 1-biphenylmethylimidazole derivatives | SANKYO CO (JP) | 1999-10-20 | — | — | CN | disclosed |
| CN-1189490-A | Process for preparing 1-biphenylmethylimidazole derivatives | SANKYO CO (JP) | 1998-08-05 | — | — | CN | disclosed |
| CN-1188645-A | Process for preparing pharmaceutical composition for treatment or prevention hypertension | SNAKYO CO LTD (JP) | 1998-07-29 | — | — | CN | disclosed |
| US-5646171-A | HYPOTENSIVE AGENTS | SANKYO COMPANY, LIMITED (JP) | 1997-07-08 | — | — | US | disclosed |
| US-5616599-A | HYPOTENSIVE AGENTS FOR CARDIOVASCULAR DISORDER | SANKYO COMPANY, LIMITED (JP) | 1997-04-01 | — | — | US | disclosed |
| CN-1065063-A | 1-Biphenylmethylimidazole derivatives, their preparation and their therapeutic use | SANKYO CO (JP) | 1992-10-07 | — | — | CN | disclosed |
| EP-0503785-A1 | 1-Biphenylimidazole derivatives, their preparation and their therapeutic use | Sankyo Company Limited (JP) | 1992-09-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176760-A1 | TRICYCLIC COMPOUNDS | PPARG, PPARD, PPARA | ALDH1A1 1421/4885HPGD 1680/4885KDM4E 2273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.